ALPHARETTA, Ga., May 12, 2014 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCBB:SNWV) has received a patent issued by the U.S. Patent and Trademark Office entitled "Methods and Devices for Cleaning and Sterilization with Shock Waves." The claims of the patent (patent number 8,685,317) relate to the use of shock waves to clean and sterilize fluids in containers and/or pipes. Specifically, shock waves are used to destroy biological contaminants, such as bacteria, viruses and other microorganisms, from different fluids. The patent life extends to September 2030.
"This new patent enlarges the reach of our intellectual property portfolio in non-medical fields," commented Kevin Richardson, Chairman of the board of directors of SANUWAVE. "Based on this patent, SANUWAVE will look for potential collaborations with interested parties in applying our shock wave technology for cleaning industrial, dirty or polluted waters and tap into the water-treatment equipment industry that according to Forbes has the potential to hit $1 trillion by 2020." Mr. Richardson added, "We believe that this new SANUWAVE patent also shows that our technology may be used to economically sterilize liquid foods, including milk, with a U.S. market of $22 billion in retail sales annually, and natural juices that account for about $92 billion as a global market."
SANUWAVE now has 38 patents (issued or pending) on focused shock waves in medical and non-medical applications.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA's Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Source:SANUWAVE Health, Inc.